Progesterone for Menopause

Progesterone in menopause care is almost never prescribed for how it makes you feel. It is prescribed to keep estrogen from doing damage. Systemic estrogen tells the uterine lining to keep growing, and with nothing opposing that signal the lining can thicken into hyperplasia and eventually into cancer. The approved indications for Prometrium are narrow: prevention of endometrial hyperplasia if you still have a uterus and are taking conjugated estrogens tablets, and separately secondary amenorrhea. Only the first is a menopause job.

The molecule inside those capsules is micronized progesterone, chemically identical to the progesterone your ovaries made before menopause and milled to a fine particle size so enough of it survives the gut. Hold onto that fact, because most of the marketing around bioidentical hormones quietly depends on you not knowing it. The generic capsule from a retail pharmacy is bioidentical progesterone. So is the brand. Micronization is a manufacturing step rather than a philosophy, and it has been on pharmacy shelves for decades.

What progesterone does not do is deliver the benefit you started hormone therapy for. Estrogen is the part acting on hot flashes, night sweats and vaginal tissue. Progesterone is the condition attached to using systemic estrogen while you still have a uterus. One product, BIJUVA, packs estradiol and progesterone into a single capsule for moderate to severe vasomotor symptoms, which is the same arrangement inside one shell instead of two prescriptions.

The evidence for endometrial protection is unusually clean, which is rare in menopause medicine. In the randomized trial printed in the Prometrium label, 358 postmenopausal participants with an intact uterus were assigned to conjugated estrogens 0.625 mg with cyclic progesterone 200 mg, to conjugated estrogens alone, or to placebo, for up to 36 months. Hyperplasia of any degree appeared in 6 percent of the combined group, 64 percent of the estrogen-alone group and 3 percent on placebo. Atypical hyperplasia ran 1 percent against 12 percent. The PEPI trial asked the same question across 596 postmenopausal participants over three years and produced the same shape of answer. On estrogen alone, simple hyperplasia reached 27.7 percent against 0.8 percent on placebo, complex 22.7 against 0.8, and atypical 11.8 against zero. Every arm that added a progestogen, including cyclic micronized progesterone at 200 mg for the first 12 days of each cycle, had hyperplasia rates similar to placebo at P equals 0.16.

Keep that contrast in view for the rest of this page. There is a large, replicated, decades-old evidence base behind the endometrial job and a much thinner one behind everything else progesterone gets credited with. When a claim about progesterone is not about protecting the lining, the evidence underneath it is almost always weaker than what you just read. That asymmetry is the single most useful thing to carry into a consultation about it.

If you have had a hysterectomy, the indication does not apply to you. Both Prometrium and Provera are approved specifically for someone who has not had a hysterectomy and is taking daily oral conjugated estrogens. No uterus means no endometrium, and no endometrium means nothing for a progestogen to protect. It gets added anyway, usually on the reasoning that hormones ought to be balanced, which is not a claim either label makes.

The second group is subtler. Using low-dose vaginal estrogen for dryness and painful sex puts you somewhere different from using systemic estrogen for hot flashes. The 2022 North American Menopause Society position statement recommends low-dose vaginal estrogen for genitourinary symptoms where there is no indication for systemic hormone therapy, and the 2019 Lancet meta-analysis found excess breast cancer risk for every hormone therapy type except vaginal estrogens. Vaginal product labels still carry class-wide warnings written for systemic use, so read them with that in mind and settle it with your prescriber.

Adding a hormone you have no indication for is not a neutral act. In the 875-participant trial summarized in the Prometrium label, the arm taking cyclic progesterone with conjugated estrogens reported breast tenderness at 27 percent against 6 percent on placebo, dizziness at 15 against 9, and abdominal bloating at 12 against 5. Some of that belongs to the estrogen rather than the progesterone. All of it is a cost you are paying, and it buys nothing when there is no lining at risk.

This is the argument you will meet most often online, usually with the conclusion already attached. The honest version is that it is unsettled. Medroxyprogesterone acetate, sold as Provera, and micronized progesterone, sold as Prometrium, carry the identical approved indication for preventing endometrial hyperplasia alongside daily conjugated estrogens 0.625 mg. Nothing in either label ranks one above the other, and PEPI protected the endometrium with both.

The case for micronized progesterone rests largely on the E3N cohort, where breast cancer relative risk was 1.00 with a confidence interval of 0.83 to 1.22 for estrogen with progesterone, against 1.69 and 1.50 to 1.91 for estrogen with other progestagens. That is a big study and a striking gap. It is also observational, meaning nobody was randomized and who takes which hormone in France is not decided by a coin. A 2026 review still describes micronized progesterone as showing a more favorable profile, drawing on the same class of evidence.

Then the counterweights, which get quoted far less. The 2019 Lancet meta-analysis of worldwide epidemiological data found excess breast cancer risk attached to every menopausal hormone type except vaginal estrogens, micronized progesterone included. And a systematic review of 28 studies concluded that continuous combined therapy looks low risk for endometrial cancer but possibly not when micronized progesterone is used, which points the other way entirely. Two organs, two directions, and no head-to-head trial to arbitrate.

The label regimen is specific: 200 mg as a single bedtime dose for 12 days sequentially per 28-day cycle, alongside daily conjugated estrogens. The cyclic approach has its tradeoff built in. Twelve nights of progestogen sheds the lining, so a withdrawal bleed arrives on a schedule in the days after you stop. Some would rather have a predictable period and take less drug overall. Plenty, years past a final period, have no interest in bleeding again.

The alternative most prescribers reach for is 100 mg every night with no break, aiming at no bleeding at all. It is widely used and it is off-label: the Prometrium dosage section describes only the cyclic 12-day course for endometrial protection, plus a 400 mg 10-day course for secondary amenorrhea. Continuous dosing tends to bring irregular spotting for the first several months before it settles down. Bleeding that starts after a stable stretch is not something to wait out; it needs assessing.

The regimen may not be risk-neutral either. In the 2019 Lancet analysis, during years five to fourteen of current use, daily progestagen carried a relative risk of 2.30 against 1.93 for less frequent progestagen, with heterogeneity below 0.0001. In absolute terms the authors estimated roughly one extra breast cancer per 50 taking estrogen with daily progestagen for five years from age 50, against one per 70 with intermittent progestagen and one per 200 on estrogen alone. Observational again, and still a reason to have the conversation rather than accept a default.

The peanut oil is not a footnote. Every standalone oral progesterone capsule label on DailyMed, brand and generic alike, lists peanut oil among its inactive ingredients, and Prometrium states plainly that it is contraindicated if you are allergic to peanuts. That one rules the drug out entirely. The one oral exception found is BIJUVA, the estradiol and progesterone combination capsule, whose inactive list runs to medium-chain triglycerides and lauroyl PEG-32 glycerides with no peanut oil, though it does contain soybean lecithin.

Bedtime dosing has a reason behind it. The label warns of transient dizziness and drowsiness and directs a single daily dose at bedtime, with caution around driving and machinery. Some read that sedation as a bonus. Treat it as a dosing constraint first, because moving a 200 mg capsule to the morning to spread it out works directly against the instruction the label gives.

The warning picture is mid-change and worth checking yourself. On 10 November 2025 the FDA requested labeling changes for menopausal hormone therapies, and the removals are landing one product at a time. Prometrium's label published 27 July 2026 carries no boxed warning. A generic progesterone label published a week later, on 3 August 2026, still carries the full box on cardiovascular disorders, breast cancer and probable dementia, and so does Provera's June 2026 label. A recent publication date does not mean updated content, and the gap between two labels right now is administrative rather than a verdict on either drug.

Progesterone gets prescribed on its own for sleep and for hot flashes, and this is where the ground gets thin quickly. The sleep study invoked most often was a crossover experiment in eight postmenopausal participants.

Eight. It reported changes in sleep architecture under experimental disturbance and no effect on undisturbed sleep. It is a physiology finding rather than a reason to expect your own insomnia to lift.

Vasomotor symptoms have one reasonable trial behind them. Hitchcock and Prior randomized 133 healthy volunteers aged 44 to 62 to 300 mg of progesterone at bedtime or placebo for 12 weeks, and found a mean adjusted difference in hot flash score of 4.3 points favoring progesterone, with a confidence interval of 1.9 to 6.6. It is a genuine randomized result. It is also a single 12-week study in a screened group, with nothing to say about what happens at a year.

Neither use appears as an indication on any progesterone label, which is not damning in itself since off-label prescribing is legal and routine. What should give you pause is being sold either one as established. If sleep is your main reason for considering progesterone, ask what the prescriber expects, on what evidence, and what the plan is if nothing changes after three months.

Bioidentical is a word about chemistry. It tells you nothing about whether a compounding pharmacy was involved. Micronized progesterone inside an approved capsule is structurally identical to the progesterone your ovaries used to make, and there is no more bioidentical version out there to go and find. When a clinic offers compounded bioidentical progesterone as an upgrade on the pharmacy product, the upgrade being described is marketing rather than pharmacology, because the molecule at both ends is the same one.

The regulatory difference is real and runs the other way. The FDA states that compounded drugs are not FDA-approved, which means the agency does not verify their safety, effectiveness or quality before they reach the market. A compounded progesterone cream or capsule has no approved label, no standardized strength testing behind each batch, and no trial like the 36-month one that sits under Prometrium. The 2020 National Academies review was commissioned by the FDA to examine that gap, and a physician review of its findings walks through how the industry grew after 2002.

There is a narrow legitimate case, and it is worth naming. A documented peanut allergy where the combination capsule does not suit you, or an intolerance to an inactive ingredient present in every approved product, is exactly what compounding exists for, and a prescriber can make that call with you. Those are specific clinical reasons. Choosing a compounded product because someone described it as more natural is a different thing entirely.

CMS publishes the National Average Drug Acquisition Cost, which is what retail pharmacies actually pay for a drug. It is not your price at the counter: it excludes the dispensing fee, the pharmacy's margin and whatever your plan does next. As a floor it is still the most honest published number available. At the rates in the file published on 2 September 2026, generic progesterone runs $0.23117 for a 100 mg capsule and $0.41702 for 200 mg, both classified as generic in the same file.

Brand Prometrium in that same file is $15.92050 for 100 mg and $30.41654 for 200 mg. That is roughly 69 times the generic at 100 mg and roughly 73 times at 200 mg, for the identical molecule at the identical strength from the same dataset. If a prescription comes back written for the brand, asking whether the generic is acceptable is probably the highest-value question on this page.

Run the regimens and the drug itself stays cheap either way. Continuous 100 mg nightly works out near $6.94 a month at that acquisition cost, cyclic 200 mg for 12 days near $5.00 a cycle, and medroxyprogesterone 10 mg at $0.14817 a tablet is cheaper still. No monthly telehealth price appears on this page because none was verified for it. What you actually pay turns on the visit fee, the plan and the pharmacy, and those vary far more than the hormone does.

Progesterone is not a standalone decision. It follows from your estrogen, so a prescriber worth the visit will establish four things before writing anything: whether you have a uterus, whether your estrogen is systemic or local, whether you have a peanut allergy, and whether you would rather bleed on a schedule or accept months of unpredictable spotting. If none of that comes up in the consultation, that tells you something about the consultation.

For a remote visit the criteria are the same as in a clinic. Look for a US-licensed clinician who reads your full history rather than a form that routes straight to one fixed regimen, who records the indication in writing, who will send a generic unless there is a stated reason not to, and who gives you a way to report bleeding without paying for another appointment. That last one matters more than it sounds, because abnormal genital bleeding of unknown cause is a listed contraindication on both labels.

Nothing here is medical advice, and whether progesterone fits your situation is a call for you and a prescriber. Two hard limits are worth knowing before that conversation.

Both Prometrium and Provera are contraindicated if you have known, suspected or previous breast cancer, and both are contraindicated in active or past deep vein thrombosis, pulmonary embolism, stroke or heart attack.